The education library
Masteron and drostanolone: historical evidence and unanswered questions
Educational evidence summary, not personal medical advice. AI-assisted research and editorial preparation by AnabolicRX. Sources checked 23 October 2026. No independent clinical review completed. Current Canadian product authorization is not established by this article.
Identity and terminology
Drostanolone is also called dromostanolone. The propionate formulation is associated with the name Masteron. A 2020 chemistry paper identifies it as a synthetic anabolic-androgenic steroid derived from dihydrotestosterone. That paper concerns crystal forms, not a clinical trial proving medical benefits or safety. Chemical characterization and clinical evidence answer different questions. Primary chemistry study, 2020
This profile concentrates on the historical propionate research. It does not assume that other formulations share an identical evidence base. It also does not treat a brand name on an unverified product as proof of its identity or composition.
Historical medical role
The US National Cancer Institute's SEER drug database describes dromostanolone propionate as a hormonal agent used for palliation of advanced, metastatic, inoperable breast cancer in selected postmenopausal women. Palliation describes a treatment objective in serious illness; it is not a claim of cure. This database entry documents a medical role but does not establish that the drug is a current preferred treatment. NCI SEER drug record
The historical clinical literature needs to be read in that context. It involves cancer populations and frequently combinations with other drugs, not isolated comparisons in healthy adults. Claims about general performance or physique outcomes cannot be derived from those cancer studies.
What a controlled 1978 trial found
A controlled study compared drostanolone, nandrolone and testololactone in 91 patients with advanced breast cancer. The abstract reports no difference in efficacy between the three drugs. Average remission rates were 24% at four weeks and 46% at sixteen weeks. However, cyclophosphamide was added during the later interval. Wolff and Rieche, 1978
The later remission rate must not be represented as the effect of drostanolone alone: another anticancer treatment had been introduced, and the figure was an average across groups. Likewise, the absence of a detected difference does not prove identical effectiveness. The accessible abstract does not provide enough detail about allocation, subgroup sizes or uncertainty to make that stronger claim.
These results establish that clinical responses were studied in advanced cancer. They do not establish a survival advantage, prevention of cancer or superiority to modern treatments. Those are separate questions requiring different evidence.
Combination studies and missing reports
A 1982 randomized study included 98 postmenopausal women. It compared tamoxifen plus drostanolone propionate, chemotherapy, and both approaches together. The indexed abstract states that hormone receptors had not been assessed. The outcomes were not fully retrieved during this review, so this review records the design without asserting its results. Clavel and colleagues, 1982
Even with the full report, a combination arm would not isolate drostanolone's contribution unless the comparison allowed that inference. Receptor information would also matter when comparing an older population with contemporary studies selected by tumor biology.
A 1968 trial citation describes a blinded study of 68 patients receiving dromostanolone and fluorometholone. A 1970 report concerns drostanolone propionate in disseminated breast cancer. Neither accessible citation supplied enough outcome information for this review to summarize benefit or harm. Their existence is recorded as a research lead, not counted as positive evidence. 1968 trial citation 1970 report citation
Safety: separate evidence about the class from evidence about this drug
The retrieved drostanolone trial abstracts do not provide a sufficiently detailed, contemporary safety assessment. That is a gap, not evidence that adverse effects are absent. A reliable profile still needs a verified product label or full clinical reports covering virilization, reproductive effects, cardiovascular outcomes, liver findings, interactions and contraindications.
Broader androgen research provides relevant context but cannot supply drostanolone-specific event rates. The prospective HAARLEM study followed 100 men using androgens and assessed reproductive hormones and semen. It found substantial disruption of sperm production, with recovery of sperm measures generally taking longer than recovery of circulating testosterone. Multiple exposures and the observational design limit attribution to an individual compound. HAARLEM study, 2021
The distinction matters: a blood-test value returning toward normal is not the same as demonstrated fertility recovery, and group observations cannot guarantee an individual's outcome. This review provides no recovery regimen or timeline to use as a personal treatment plan.
A published myocardial-infarction case included drostanolone among many simultaneous drug exposures. Such a report can flag serious harm in a real clinical setting, but cannot identify drostanolone as the independent cause or measure its risk. It would be misleading to turn it into either a molecule-specific certainty or reassurance that the other drugs were responsible. Primary case report, 2015
Why “anti-estrogen” needs careful interpretation
Historical use in breast cancer does not make drostanolone interchangeable with every medicine that affects estrogen signaling. A clinical effect in a selected tumor population does not establish that the drug safely prevents hormonal adverse effects from other substances. The reviewed evidence does not justify that practical claim, and this profile provides no such instructions.
This summary does not provide a comprehensive pharmacology review. Receptor activity, laboratory findings and demonstrated human outcomes are different forms of evidence; a simplified label is not a treatment recommendation.
Canadian context
Canada's Controlled Drugs and Substances Act places anabolic steroids in Schedule IV. This review has not established current Canadian product authorization for drostanolone. Search-engine results and foreign records cannot replace a verified Canadian product record, and a missing result in this research is not proof of absence. Official Canadian schedule Health Canada Drug Product Database
Controlled-substance classification, authorization for sale and an appropriate medical indication are different matters. This review does not offer sourcing or legal advice about an individual's circumstances.